Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These results indicate that NK4 elicits tumor-growth suppression in vivo through its anti-angiogenic activity and anti-HGF activity and that NK4 gene transfer can be an effective tool in the treatment of cancer.
|
11829525 |
2002 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The controlled release of NK4 plasmid DNA suppressed angiogenesis and increased the cell apoptosis in the tumor tissue while it enhanced and prolonged the NK4 protein level in the blood circulation.
|
15290849 |
2004 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, NK4 gene therapy is a promising strategy to treat HCC based on the pleiotropic functions of NK4 interfering with tumor growth, invasion, metastasis and angiogenesis.
|
15905856 |
2005 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The repetitive delivery and expression of NK4 gene inhibited angiogenesis and invasiveness of colon cancer cells in subcutaneous tumor tissue and this was associated with suppression of primary tumor growth.
|
17467663 |
2007 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although successful tumor inhibition by NK4 gene expression in tumor models has been demonstrated, the effects of systemic NK4 gene introduction are yet to be addressed.
|
19438869 |
2009 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Micro-RNA-205 induced the expression of tumor suppressor genes IL24 and IL32 at both the messenger RNA and protein levels.
|
20737563 |
2010 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
NK4 gene therapy combined with cisplatin inhibits tumour growth and metastasis of squamous cell carcinoma.
|
21273587 |
2011 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The inhibitory effect of IL-32γ on tumor growth was associated with the inhibition of constitutive activated nuclear transcription factor-κB (NF-κB) and of signal transducer and activator of transcription 3 (STAT3).
|
21423208 |
2011 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Interestingly, elevated levels of IL-32 transcripts in fine needle aspirates of tumor tissue have also been correlated with objective clinical responses in cancer patients receiving immunotherapy.
|
21760628 |
2011 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
There is increase in p-p38MAPK activation underlying IL-32 expression in tumor P=0.004, but no change in total p38 MAPK in malignant esophagus.
|
23107826 |
2013 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor tissues isolated from LPS-injected mice inoculated with IL-32γ-overexpressing colon cancer cells potentiated the expression levels of pro-apoptotic proteins such as cleaved caspase-3, 9 and Bax, but decreased that of Bcl-2.
|
23255489 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We showed that patients with tumor expressing high amounts of IL32 exhibit decreased disease-free periods (20.5 mo vs. 41 mo, P = 0.0041) and overall survival (P = 0.0359) in comparison with individuals with weak IL32 tumor expression.
|
23359495 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Multivariate analysis demonstrated that IL-32 is one of the prognostic markers (p < 0.03) for gastric cancer, in addition to nodal involvement and tumor depth.
|
23479179 |
2013 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Results demonstrate substantial IL-32 expression in TC tumor tissue.
|
23486016 |
2013 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
By performing immunohistochemical assays on primary breast cancer samples, we found that the level of IL-32β expression was positively correlated with tumor size, number of lymph node metastases and tumor stage.
|
24114327 |
2013 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
IL-32 mRNA expression levels in lesional skin of MF patch, plaque, and tumor were increased compared with those of normal skin, which positively correlated with CCL17 and CCL18 mRNA expression levels.
|
24226419 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The proinflammatory cytokine interleukin-32 (IL-32) is a novel tumor marker highly expressed in various human carcinomas, including gastric cancer.
|
24602839 |
2014 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The analysis revealed an interaction between IL8 -251A>T and IL32 rs28372698 SNPs among cases with moderately- or well-differentiated tumors.
|
24982364 |
2014 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
IL32 expression and Treg infiltration in ESCC play an important synergistic role in tumor growth and invasion.
|
25964580 |
2015 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Other studies suggested that IL-32 decreases tumor development including cervical cancer, colon cancer and prostate cancer, melanoma, pancreatic cancer, liver cancer and chronic myeloid leukemia.
|
28223235 |
2017 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our data suggest a possible survival mechanism by the splicing of IL-32γ to IL-32β and also IL-6, IL-8, and CXCR1 signaling pathways to reverse the proapoptotic effect of the IL-32γ isoform, leading to tumor cell survival and thus favoring tumor progression.
|
29037857 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Hence, it can be concluded that IL-32θ is an anti-inflammatory cytokine that can act as a tumor suppressor and can play vital role in colon cancer therapies.
|
29218075 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In an in vivo carcinogen induced lung tumor model, tumor growth was inhibited in IL-32γ overexpressed mice with elevated TIMP-3 expression and hypomethylation accompanied with reduced NF-κB activity.
|
29467412 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Some IL-32 isoforms have been linked to disease outcome and were shown to positively influence tumor development and progression in various different malignancies, including gastric, breast and lung cancers.
|
29747940 |
2018 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of IL-32 is regulated by numerous factors, including genetic variations, hypoxia and acidosis in the tumour microenvironment.
|
29930712 |
2018 |